![]() |
|
|
Vol. 289, Issue 1, 412-416, April 1999
Department of Physiology and Neuroscience, Medical University of
South Carolina, Charleston, South Carolina
Receptor subtype nonselective metabotropic glutamate receptor (mGluR)
agonists have been shown to regulate the release of dopamine. The eight
mGluR subtypes have been pharmacologically categorized into three
groups, and the present study used in vivo microdialysis to examine the
capacity of mGluR subgroup-selective drugs to modulate the
extracellular levels of dopamine in the nucleus accumbens. By
administering the drugs in the dialysis buffer, it was found that the
group 3 mGluR agonist L-amino-4-phosphonobutyrate produced a dose-dependent reduction in extracellular dopamine, whereas
the group 1 agonist 3,5-dihydroxyphenylglycine was ineffective. The
group 2 agonist
(2S,1'R,2'R,3'R)-2-(2,3-dicarboxycyclopropyl)glycine produced a reduction that was biphasic with respect to dose. The group
2/3 antagonist
-methyl-4-phosphnophenylglycine elicited a
dose-dependent increase in extracellular dopamine that was antagonized by coperfusion with either the L-type calcium channel
blocker diltiazem or the group 3 agonist
L-amino-4-phosphonobutyrate. These data demonstrate that
group 3 and to a lesser extent group 2 mGluR may presynaptically
regulate dopamine release or reuptake. Moreover, there exists
significant in vivo glutamatergic tone on group 2/3 mGluRs to suppress
extracellular dopamine levels.